These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 25743805)
1. Overexpression of Tbx3 predicts poor prognosis of patients with resectable pancreatic carcinoma. Wang HC; Meng QC; Shan ZZ; Yuan Z; Huang XY Asian Pac J Cancer Prev; 2015; 16(4):1397-401. PubMed ID: 25743805 [TBL] [Abstract][Full Text] [Related]
2. High level of FOXC1 expression is associated with poor prognosis in pancreatic ductal adenocarcinoma. Wang L; Gu F; Liu CY; Wang RJ; Li J; Xu JY Tumour Biol; 2013 Apr; 34(2):853-8. PubMed ID: 23242609 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma. Xia JT; Wang H; Liang LJ; Peng BG; Wu ZF; Chen LZ; Xue L; Li Z; Li W Pancreas; 2012 May; 41(4):629-35. PubMed ID: 22249132 [TBL] [Abstract][Full Text] [Related]
4. Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance. Xue YZ; Sheng YY; Liu ZL; Wei ZQ; Cao HY; Wu YM; Lu YF; Yu LH; Li JP; Li ZS Tumour Biol; 2013 Apr; 34(2):895-9. PubMed ID: 23247867 [TBL] [Abstract][Full Text] [Related]
5. Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma. Yan TT; Fu XL; Li J; Bian YN; Liu DJ; Hua R; Ren LL; Li CT; Sun YW; Chen HY; Fang JY; Hong J Oncotarget; 2015 Nov; 6(35):37028-42. PubMed ID: 26498693 [TBL] [Abstract][Full Text] [Related]
6. Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients. Guo S; Jing W; Hu X; Zhou X; Liu L; Zhu M; Yin F; Chen R; Zhao J; Guo Y Int J Cancer; 2014 Mar; 134(6):1369-78. PubMed ID: 24037692 [TBL] [Abstract][Full Text] [Related]
7. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer. Jiang SH; Wang Y; Yang JY; Li J; Feng MX; Wang YH; Yang XM; He P; Tian GA; Zhang XX; Li Q; Cao XY; Huo YM; Yang MW; Fu XL; Li J; Liu DJ; Dai M; Wen SY; Gu JR; Hong J; Hua R; Zhang ZG; Sun YW Oncotarget; 2016 Jan; 7(4):4226-40. PubMed ID: 26735172 [TBL] [Abstract][Full Text] [Related]
8. Annexin A2 and CD105 expression in pancreatic ductal adenocarcinoma is associated with tumor recurrence and prognosis. Huang YK; Liu H; Wang XZ; Zhu S Asian Pac J Cancer Prev; 2014; 15(22):9921-6. PubMed ID: 25520129 [TBL] [Abstract][Full Text] [Related]
9. Expression of UbcH10 in pancreatic ductal adenocarcinoma and its correlation with prognosis. Zhao ZK; Wu WG; Chen L; Dong P; Gu J; Mu JS; Yang JH; Liu YB Tumour Biol; 2013 Jun; 34(3):1473-7. PubMed ID: 23355337 [TBL] [Abstract][Full Text] [Related]
10. KIAA1199/CEMIP/HYBID overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma. Koga A; Sato N; Kohi S; Yabuki K; Cheng XB; Hisaoka M; Hirata K Pancreatology; 2017; 17(1):115-122. PubMed ID: 28012880 [TBL] [Abstract][Full Text] [Related]
11. Prostate-specific membrane antigen as a marker of pancreatic cancer cells. Ren H; Zhang H; Wang X; Liu J; Yuan Z; Hao J Med Oncol; 2014 Mar; 31(3):857. PubMed ID: 24477651 [TBL] [Abstract][Full Text] [Related]
12. Expression and clinical significance of HSPA2 in pancreatic ductal adenocarcinoma. Zhang H; Gao H; Liu C; Kong Y; Wang C; Zhang H Diagn Pathol; 2015 Mar; 10():13. PubMed ID: 25890028 [TBL] [Abstract][Full Text] [Related]
13. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma. Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of mixed lineage kinase domain-like protein expression in the survival of patients with gastric caner. Ertao Z; Jianhui C; Kang W; Zhijun Y; Hui W; Chuangqi C; Changjiang Q; Sile C; Yulong H; Shirong C Tumour Biol; 2016 Oct; 37(10):13679-13685. PubMed ID: 27473085 [TBL] [Abstract][Full Text] [Related]
15. Preoperative High Maximum Standardized Uptake Value in Association with Glucose Transporter 1 Predicts Poor Prognosis in Pancreatic Cancer. Chikamoto A; Inoue R; Komohara Y; Sakamaki K; Hashimoto D; Shiraishi S; Takamori H; Yamashita YI; Yoshida N; Yamanaka T; Yamashita Y; Baba H Ann Surg Oncol; 2017 Jul; 24(7):2040-2046. PubMed ID: 28180987 [TBL] [Abstract][Full Text] [Related]
16. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma. Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648 [TBL] [Abstract][Full Text] [Related]
18. Identification of ANXA1 as a lymphatic metastasis and poor prognostic factor in pancreatic ductal adenocarcinoma. Liu QH; Shi ML; Bai J; Zheng JN Asian Pac J Cancer Prev; 2015; 16(7):2719-24. PubMed ID: 25854353 [TBL] [Abstract][Full Text] [Related]
19. Chondroitin sulfate proteoglycan CSPG4 as a novel hypoxia-sensitive marker in pancreatic tumors. Keleg S; Titov A; Heller A; Giese T; Tjaden C; Ahmad SS; Gaida MM; Bauer AS; Werner J; Giese NA PLoS One; 2014; 9(6):e100178. PubMed ID: 24932730 [TBL] [Abstract][Full Text] [Related]
20. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma. Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]